GE HealthCare Doses First Patient in Phase 2/3 LUMINA Trial for MRI Contrast Agent
GE HealthCare has announced that it has successfully dosed the first patient in its Phase 2/3 LUMINA clinical trial. This trial is focused on a manganese-based MRI contrast agent which is currently under FDA Fast Track designation. This development marks a significant step in advancing GE HealthCare’s innovation pipeline of novel imaging agents.
CHALFONT ST GILES, England–(BUSINESS WIRE)–GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation